Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Barter

Showing results (21-30 of 78) with videos related to

Pageof 8
Sort By:
Nuclear Receptor|May 29, 2007
The integration of lipid-sensing and anti-inflammatory effects: how the PPARs play a role in metabolic balanceAlistair V W Nunn, Jimmy Bell, Philip Barter
Atherosclerosis|June 13, 2003
High density lipoproteins (HDLs) and atherosclerosis; the unanswered questionsPhilip Barter, John Kastelein, Alistair Nunn, et al.
The American Journal of Cardiology|April 23, 2017
Effects of Torcetrapib and Statin Treatment on ApoC-III and Apoprotein-Defined Lipoprotein Subclasses (from the ILLUMINATE Trial)John Bagdade, Philip Barter, Carmen Quiroga, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|May 26, 2009
Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic reviewDiana R Chirovsky, Veronika Fedirko, Yadong Cui, et al.
Archives of Internal Medicine|October 28, 2009
Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levelsSteven A Grover, Mohammed Kaouache, Lawrence Joseph, et al.
The American Journal of Cardiology|March 21, 2003
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goalsJames Shepherd, Donald B Hunninghake, Philip Barter, et al.
Atherosclerosis. Supplements|November 9, 2004
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003James Shepherd, Donald B Hunninghake, Philip Barter, et al.
Lancet (London, England)|October 24, 2006
Correction to the FIELD study reportAnthony Keech, John Simes, Philip Barter, et al.
Nature Reviews. Endocrinology|January 25, 2012
The emerging role of HDL in glucose metabolismBrian G Drew, Kerry-Anne Rye, Stephen J Duffy, et al.
Lipids in Health and Disease|April 16, 2021
Prevalence of plasma lipid disorders with an emphasis on LDL cholesterol in selected countries in the Asia-Pacific regionZhen-Vin Lee, Elmer Jasper Llanes, Renan Sukmawan, et al.
Pageof 8

Showing results (21-30 of 78) with videos related to

Sort By:
Pageof 8
Nuclear Receptor|May 29, 2007
The integration of lipid-sensing and anti-inflammatory effects: how the PPARs play a role in metabolic balanceAlistair V W Nunn, Jimmy Bell, Philip Barter
Atherosclerosis|June 13, 2003
High density lipoproteins (HDLs) and atherosclerosis; the unanswered questionsPhilip Barter, John Kastelein, Alistair Nunn, et al.
The American Journal of Cardiology|April 23, 2017
Effects of Torcetrapib and Statin Treatment on ApoC-III and Apoprotein-Defined Lipoprotein Subclasses (from the ILLUMINATE Trial)John Bagdade, Philip Barter, Carmen Quiroga, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|May 26, 2009
Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic reviewDiana R Chirovsky, Veronika Fedirko, Yadong Cui, et al.
Archives of Internal Medicine|October 28, 2009
Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levelsSteven A Grover, Mohammed Kaouache, Lawrence Joseph, et al.
The American Journal of Cardiology|March 21, 2003
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goalsJames Shepherd, Donald B Hunninghake, Philip Barter, et al.
Atherosclerosis. Supplements|November 9, 2004
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003James Shepherd, Donald B Hunninghake, Philip Barter, et al.
Lancet (London, England)|October 24, 2006
Correction to the FIELD study reportAnthony Keech, John Simes, Philip Barter, et al.
Nature Reviews. Endocrinology|January 25, 2012
The emerging role of HDL in glucose metabolismBrian G Drew, Kerry-Anne Rye, Stephen J Duffy, et al.
Lipids in Health and Disease|April 16, 2021
Prevalence of plasma lipid disorders with an emphasis on LDL cholesterol in selected countries in the Asia-Pacific regionZhen-Vin Lee, Elmer Jasper Llanes, Renan Sukmawan, et al.
Pageof 8